Search research articles
Contact Us
Filters
Showing results (121-130 of 220) with videos related to
Page
of 22
Sort By:
British Journal of Cancer
|
October 1, 1994
A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma
N M Bleehen, A H Calvert, S M Lee, et al.
Advances in Enzyme Regulation
|
January 1, 1989
Thymidylate synthase: a target for anticancer drug design
K R Harrap, A L Jackman, D R Newell, et al.
Cancer Investigation
|
March 20, 2003
Cancer drug development in Europe: a selection of new agents under development at the European Drug Development Network
D Lacombe, A Butler-Smith, P Therasse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 4, 1999
Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels
S Ghazal-Aswad, M J Tilby, M Lind, et al.
Journal of Medicinal Chemistry
|
March 1, 1991
Quinazoline antifolates inhibiting thymidylate synthase: 4-thio-substituted analogues
T J Thornton, T R Jones, A L Jackman, et al.
Journal of Medicinal Chemistry
|
September 30, 1994
The synthesis and thymidylate synthase inhibitory activity of L-gamma-L-linked dipeptide and L-gamma-amide analogues of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)
G M Bisset, V Bavetsias, T J Thornton, et al.
Lancet (London, England)
|
May 3, 1986
Phase II trials in metastatic bladder cancer
R R Hall, A H Calvert, B De Stavola, et al.
British Journal of Cancer
|
January 1, 1997
A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer
N Siddiqui, A V Boddy, H D Thomas, et al.
Advances in Enzyme Regulation
|
January 1, 1991
Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2-methyl-N10-substituted-5,8-dideazafolates
A L Jackman, P R Marsham, R G Moran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 1998
Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro
E Marshman, D R Newell, A H Calvert, et al.
Page
of 22
Search research articles
Search
Showing results (121-130 of 220) with videos related to
Sort By:
Page
of 22
British Journal of Cancer
|
October 1, 1994
A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma
N M Bleehen, A H Calvert, S M Lee, et al.
Advances in Enzyme Regulation
|
January 1, 1989
Thymidylate synthase: a target for anticancer drug design
K R Harrap, A L Jackman, D R Newell, et al.
Cancer Investigation
|
March 20, 2003
Cancer drug development in Europe: a selection of new agents under development at the European Drug Development Network
D Lacombe, A Butler-Smith, P Therasse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 4, 1999
Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels
S Ghazal-Aswad, M J Tilby, M Lind, et al.
Journal of Medicinal Chemistry
|
March 1, 1991
Quinazoline antifolates inhibiting thymidylate synthase: 4-thio-substituted analogues
T J Thornton, T R Jones, A L Jackman, et al.
Journal of Medicinal Chemistry
|
September 30, 1994
The synthesis and thymidylate synthase inhibitory activity of L-gamma-L-linked dipeptide and L-gamma-amide analogues of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)
G M Bisset, V Bavetsias, T J Thornton, et al.
Lancet (London, England)
|
May 3, 1986
Phase II trials in metastatic bladder cancer
R R Hall, A H Calvert, B De Stavola, et al.
British Journal of Cancer
|
January 1, 1997
A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer
N Siddiqui, A V Boddy, H D Thomas, et al.
Advances in Enzyme Regulation
|
January 1, 1991
Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2-methyl-N10-substituted-5,8-dideazafolates
A L Jackman, P R Marsham, R G Moran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 1998
Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro
E Marshman, D R Newell, A H Calvert, et al.
Page
of 22